rian.ie - Results

A A A

Current Search:	'Cancer' in all fields;

Displaying Results 226 - 250 of 3157 on page 10 of 127

Mark

Promotion of a cancer-like phenotype, through chronic exposure to inflammatory cytokines and hypoxia in a bronchial epithelial cell line model. (2016)

GRAY, STEVEN; O'BYRNE, KEN; BAIRD, ANNE-MARIE

Mark

Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies. (2017)

Toomey, Sinead; Eustace, Alex J; Fay, Joanna; Sheehan, Katherine M; Carr, Aoife; Milews...

Toomey, Sinead; Eustace, Alex J; Fay, Joanna; Sheehan, Katherine M; Carr, Aoife; Milewska, Malgorzata; Madden, Stephen F; Teiserskiene, Ausra; Kay, Elaine W; O'Donovan, Norma; Gallagher, William; Grogan, Liam; Breathnach, Oscar; Walshe, Janice; Kelly, Catherine; Moulton, Brian; Kennedy, M John; Gullo, Guiseppe; Hill, Arnold DK; Power, Colm

Abstract:

The original article is available at www.biomedcentral.com
BACKGROUND: The Cancer Genome Atlas analysis revealed that somatic EGFR, receptor tyrosine-protein kinase erbB-2 (ERBB2), Erb-B2 receptor tyrosine kinase 3 (ERBB3) and Erb-B2 receptor tyrosine kinase 4 (ERBB4) gene mutations (ERBB family mutations) occur alone or co-occur with somatic mutations in the gene encoding the phosphatidylinositol 3-kinase (PI3K) catalytic subunit (PIK3CA) in 19% of human epidermal growth factor receptor 2 (HER2)-positive breast cancers. Because ERBB family mutations can activate the PI3K/AKT pathway and likely have similar canonical signalling effects to PI3K pathway mutations, we investigated their combined impact on response to neoadjuvant HER2-targeted therapies. METHODS: Baseline tumour biopsies were available from 74 patients with HER2-positive breast cancer who were enrolled in the phase II TCHL neoadjuvant study (ICORG 10-05) assessing TCH (...

https://epubs.rcsi.ie/molmedart/35

Mark

Patients’ bowel symptom experiences and self-care strategies following sphincter-saving surgery for rectal cancer (2014)

Landers, Margaret; McCarthy, Geraldine; Livingstone, Vicki; Savage, Eileen

Mark

Formulation and evaluation of anisamide-targeted amphiphilic cyclodextrin nanoparticles to promote therapeutic gene silencing in a 3D prostate cancer bone metastases model (2016)

Evans, James C.; Malhotra, Meenakshi; Fitzgerald, Kathleen A.; Guo, Jianfeng; Cronin, M...

Mark

Gold nanoparticles enlighten the future of cancer theranostics (2017)

Guo, Jianfeng; Rahme, Kamil; He, Yan; Li, Lin-Lin; Holmes, Justin D.; O'Driscoll, ...

Mark

Dye-doped silica nanoparticles for cancer cell staining and detection (2017)

O'Connell, Claire

Mark

“The generation of anti-prostate cancer-specific antibodies for improved disease diagnosis” (2016)

Byrne, Hannah

Mark

Knowledge, attitudes, and practices regarding cervical cancer and screening among women visiting primary health care Centres in Bahrain. (2018)

Jassim, Ghufran A; Obeid, Alaaeddin; Al Nasheet, Huda A

Mark

SLC22A3 polymorphisms do not modify pancreatic cancer risk, but may influence overall patient survival. (2017)

Mohelnikova-Duchonova, Beatrice; Strouhal, Ondrej; Hughes, David J; Holcatova, Ivana; O...

SLC22A3 polymorphisms do not modify pancreatic cancer risk, but may influence overall patient survival. (2017)

Mohelnikova-Duchonova, Beatrice; Strouhal, Ondrej; Hughes, David J; Holcatova, Ivana; Oliverius, Martin; Kala, Zdenek; Campa, Daniele; Rizzato, Cosmeri; Canzian, Federico; Pezzilli, Raffaele; Talar-Wojnarowska, Renata; Malecka-Panas, Ewa; Sperti, Cosimo; Federico Zambon, Carlo; Pedrazzoli, Sergio; Fogar, Paola; Milanetto, Anna Caterina; Capurso, Gabriele; Delle Fave, Gianfranco; Valente, Roberto

Abstract:

The original article is available at www.nature.com
Expression of the solute carrier (SLC) transporter SLC22A3 gene is associated with overall survival of pancreatic cancer patients. This study tested whether genetic variability in SLC22A3 associates with pancreatic cancer risk and prognosis. Twenty four single nucleotide polymorphisms (SNPs) tagging the SLC22A3 gene sequence and regulatory elements were selected for analysis. Of these, 22 were successfully evaluated in the discovery phase while six significant or suggestive variants entered the validation phase, comprising a total study number of 1,518 cases and 3,908 controls. In the discovery phase, rs2504938, rs9364554, and rs2457571 SNPs were significantly associated with pancreatic cancer risk. Moreover, rs7758229 associated with the presence of distant metastases, while rs512077 and rs2504956 correlated with overall survival of patients. Although replicated, the association for rs9364554 did no...

https://epubs.rcsi.ie/physiolart/133

Mark

The role of vitamin D and UVB on the risk and survival of oesophageal and gastric cancer (2018)

O' SULLIVAN, FIONA

Mark

The association between complications and quality of life after mastectomy and breast reconstruction for breast cancer (2017)

Browne, John P.; Jeevan, Ranjeet; Gulliver-Clarke, Carmel; Pereira, Jerome; Caddy, Chr...

Mark

Self-management strategies used by head and neck cancer survivors following completion of primary treatment: a directed content analysis (2017)

Dunne, Simon; Mooney, Orla; Coffey, Laura; Sharp, Linda; Timmons, Aileen; Desmond, Deir...

Mark

Gene therapy with RALA/iNOS composite nanoparticles significantly enhances survival in a model of metastatic prostate cancer (2018)

McCrudden, Cian M; McBride, John W; McCaffrey, Joanne; McErlean, Emma M; Dunne, Nichola...

Mark

South Central Strategic Health Authority: Cancer inequalities (2007)

Oxford Cancer Intelligence Unit

Mark

Improving outcomes for people with skin tumours including melanoma (update) (2010)

Northern Ireland Cancer Network (NICaN)

Mark

University Research Proposal Submission Topics 2010 (2010)

Northern Ireland Cancer Network (NICaN)

Mark

Applications of Raman spectroscopy to the urinary bladder for cancer diagnostics (2014)

Kerr, Laura; Domijan, Katarina; Cullen, Ivor; Hennelly, Bryan M.

Mark

Promoting testicular cancer awareness and screening: a systematic review of interventions (2016)

Saab, Mohamad M.; Landers, Margaret; Hegarty, Josephine

Mark

Targeting cancer stem cells in the clinic: Current status and perspectives. (2018)

Annett, Stephanie; Robson, Tracy

Mark

Targeting Aberrant Transcription in Invasive Lobular Carcinoma Breast Cancer (2018)

Walsh, Louise

Mark

ADAM22 as a predictive marker for endocrine resistant metastatic breast cancer and an LGI1 mimetic as a companion therapeutic (2018)

Doherty, Ben

Mark

Investigation of the Functional Roles of Calcium Channels, Inflammatory Cytokines and Tumour Micro-Environmental Factors in a Human In Vitro Model of Breast Cancer Calcification (2018)

O'Grady, Shane

Mark

Analytical validation of a prognostic prostate cancer gene expression assay using formalin fixed paraffin embedded tissue. (2018)

Medlow, Paul W; Steele, Christopher J; McCavigan, Andrena M; Reardon, Wesley; Brown, Ch...

Analytical validation of a prognostic prostate cancer gene expression assay using formalin fixed paraffin embedded tissue. (2018)

Medlow, Paul W; Steele, Christopher J; McCavigan, Andrena M; Reardon, Wesley; Brown, Christopher M; Lambe, Shauna M; Ishiy, Felipe AA; Walker, Steven M; Logan, Gemma E; Raji, Olaide Y; Berge, Viktor; Katz, Betina; Kay, Elaine W; Sheehan, Katherine M; Watson, Ronald W; Harkin, Denis P; Kennedy, Richard D; Knight, Laura A

Abstract:

The original article is available at <a href="https://www.biomedcentral.com/">www.biomedcentral.com</a>
BACKGROUND: There is a clear need for assays that can predict the risk of metastatic prostate cancer following curative procedures. Importantly these assays must be analytically robust in order to provide quality data for important clinical decisions. DNA microarray based gene expression assays measure several analytes simultaneously and can present specific challenges to analytical validation. This study describes the analytical validation of one such assay designed to predict metastatic recurrence in prostate cancer using primary formalin fixed paraffin embedded tumour material. METHODS: Accuracy was evaluated with a method comparison study between the assay development platform (Prostate Disease Specific Array) and an alternative platform (Xcel™ mic...

https://epubs.rcsi.ie/pathart/11